Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. [PDF]
Busch C+5 more
europepmc +1 more source
Myleran in Treatment of Chronic Myeloid Leukaemia [PDF]
H. T. Swan, E. K. Blackburn, G. M. King
openaire +3 more sources
CD86, the double agent: Significance of CD86 expression in B‐cell malignancies
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna+4 more
wiley +1 more source
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA
E. Joanna Baxter
openalex +1 more source
In vivo and in vitro studies onAnaplasma phagocytophiluminfection of the myeloid cells of a patient with chronic myelogenous leukaemia and human granulocytic ehrlichiosis [PDF]
M Bayard-Mc Neeley+11 more
openalex +1 more source
The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia. [PDF]
Lebecque B+13 more
europepmc +1 more source
What's New? Significant advances in childhood cancer survival have transformed outcomes for many children globally. However, emerging evidence suggests that, even in settings with universal healthcare, these gains are not equally distributed. Here, the authors focused on childhood cancer survival in Germany, using data from the German Childhood Cancer ...
Maike Wellbrock+7 more
wiley +1 more source
Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis. [PDF]
Graf R+3 more
europepmc +1 more source